Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta - GBI Research Reports

Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta

Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta - GBI Research Reports
Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
Published Nov 22, 2011
240 pages — Published Nov 22, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta, which provides insights into the global pain management therapeutics market and market forecasts until 2017. The report provides an in-depth analysis of the top eight therapeutic indications for which pain management drugs are often prescribed, which includes fibromyalgia, neuropathic pain, migraine, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post-operative pain. The report also examines the global pain management therapeutics treatment usage patterns for the covered indications. In addition, the report also includes insights into the pain management therapeutics R&D pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.

The global pain management therapeutics market has huge potential for growth due to the large population that is affected by medically significant pain. The market is growing at a moderate growth rate, driven by the cancer pain, low back pain and post-operative pain relief markets. In 2010, the global pain management therapeutics market was estimated at $28.6 billion, representing a CAGR of 5.3% between 2002 and 2010. The post-operative pain relief market, with sales of $5.9 billion in 2010, accounted for one fifth of the total pain management therapeutics market. The low back pain market, with sales of $4.9 billion, was the second largest market segment, with a share of 17% of the worldwide pain management therapeutics market. The low back pain market is followed by the cancer pain and neuropathic pain relief markets, accounting for 16% each of the global pain management therapeutics market.

The global pain management market is driven by anticonvulsant Lyrica and anti-depressant Cymbalta, which are expected to expire in 2013. By 2017, the global pain management therapeutics market is forecast to generate sales of $35.1 billion, representing a CAGR of 3.0% between 2010 and 2017. Other blockbuster drugs that are likely to drive the market in the forecast period include UCB Groups Vimpat (lacosamide), Tevas Fentora (fentanyl), J&Js Nucynta (tapentadol), Pfizers Remoxy (oxycodone hydrochloride) and Orexos Abstral (fentanyl).

Scope

- Data and analysis on the pain therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the pain management therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the therapeutic landscape, which covers fibromyalgia, neuropathic pain, migraine, cancer pain, osteoarthritis pain, rheumatoid arthritis pain, low back pain and post-operative pain therapeutics, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global pain management therapeutics market, which includes companies such as Pfizer, Johnson & Johnson, Teva, Eli Lilly and several mid-size players such as Purdue Pharma, Endo Pharmaceuticals, and Forest Laboratories.
- Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global pain management therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying

  
Source:
Document ID
GBIHC128MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents314
  List of Tables74
  List of Figures116
Pain Management Therapeutics Market - Introduction172
  GBI Research Report Guidance181
Pain Management Therapeutics Market - Market Overview1920
  Introduction192
  WHO (World Health Organization) Pain Ladder211
  Risk Evaluation and Mitigation Strategy (REMS)221
  Revenue231
  Major Marketed Pain Management Drugs241
    Lyrica (pregabalin)251
      Overview251
      Mechanism of Action251
      Efficacy251
      Safety261
    Cymbalta (duloxetine)261
      Overview261
      Efficacy261
      Safety261
    Celebrex (celecoxib)261
      Efficacy271
      Safety271
    Voltaren Gel (diclofenac sodium)271
      Overview271
      Efficacy271
      Safety271
    Imitrex(sumatriptan succinate)271
      Overview271
    Savella (milnacipran hydrochloride)281
      Overview281
    Lidoderm (lidocaine patch)281
      Overview281
    Qutenza (capsaicin)281
      Overview281
    Zomig (zolmitriptan)291
      Overview291
    Maxalt (rizatriptan benzoate)291
      Overview291
  Annual Cost of Therapy301
  Treatment Usage Patterns312
    Diseased Population331
    Treatment Seeking Population341
    Diagnosed Population351
    Prescription Population361
  Drivers and Restraints of the Pain Management Therapeutics Market371
    Drivers371
      Rising Elderly Population371
      Increased Awareness of Pain Indications371
      Strong Product Pipeline381
    Restraints381
      Pain Medications, Particularly Opioids, are Associated with Several Side Effects381
      Difficulty in Pain Diagnosis Leads to Low Prescription Rates381
      Availability of Generics381
Pain Management Therapeutics Market - Therapeutic Landscape39117
  Pain Management Therapeutics Market for Fibromyalgia391
    Introduction391
    Revenue401
    Branded vs. Generic Share411
    Annual Cost of Therapy421
    Treatment Flow Algorithm431
    Treatment Usage Patterns442
      Diseased Population461
      Treatment Seeking Population471
      Diagnosed Population481
      Prescription Population491
    Geographical Segmentation503
    Drivers and Restraints for the Fibromyalgia Market531
      FDA Approval of Lyrica, Cymbalta and Savella to Propel the Market531
      Elderly Populations will Drive Prevalence531
      Improvements in Awareness and Resultant Diagnosis Levels will Drive the Market531
      Substantial Unmet Need Increases the Market Potential541
    Restraints for the Fibromyalgia Pain Relief Market541
      Limitations in the Efficacy of Existing Drugs Can Potentially Lead to Low Prescription541
      Inadequate Knowledge of Disease Progression Hinders the Development of Drugs with Better Efficacy541
  Pain Management Therapeutics for Neuropathic Pain541
    Introduction541
    Revenue551
    Branded Vs Generic Share561
    Annual Cost of Therapy571
    Treatment Flow Algorithm581
    Treatment Usage Patterns591
      Diseased Population601
      Treatment Seeking Population611
      Diagnosed Population621
      Prescription Population631
    Geographical Segmentation642
    Drivers and Restraints for the Neuropathic Pain Market661
    Drivers671
      Ageing Populations and Increasing Prevalence of Diabetes and HIV671
      More Active Treatment Seeking Behavior to Drive Increase in Patient Volumes671
      Increased Uptake of Lyrica (pregabalin) will Drive the Neuropathic Pain Management Market671
    Restraints671
      Non-availability of Accurate Tools that Aid Diagnosis is a Hindrance for Market Growth671
  Pain Management Therapeutics Market for Migraine681
    Introduction681
    Revenue681
    Branded Vs Generic Share691
    Annual Cost of Therapy702
    Treatment Flow Algorithm721
    Treatment Usage Patterns732
      Diseased Population751
      Treatment Seeking Population761
      Diagnosed Population771
      Prescription Population781
    Geographical Segmentation792
    Drivers and Restraints for the Migraine Market811
    Drivers821
      The Increasing Awareness will Result in an Increasing Prescription Rate821
    Restraints821
      Low Treatment Seeking Behavior and Diagnosis Rate Restrain the Growth in Prescription Population821
      Falling Prices of Migraine Treatment will Restrain the Market by Offsetting the Impact of Increasing Volume821
      Alternative Medicine and Self-Care Techniques will Restrict the Market for Migraine Pain Medications821
  Pain Management Therapeutics Market for Cancer Pain821
    Introduction821
      The Cancer Pain Drug Market is Fuelled by Opioids831
    Revenue832
    Branded Vs Generic Share851
    Annual Cost of Therapy861
    Treatment Flow Algorithm871
    Treatment Usage Patterns882
      Diseased Population901
      Treatment Seeking Population911
      Diagnosed Population921
      Prescription Population924
    Geographical Segmentation962
    Drivers and Restraints for the Cancer Pain Market981
    Drivers991
      Rising Incidence of Cancer Drives the Market991
      New Modes of Delivery Will Help in Better Management of Pain for a Longer Duration991
      Unmet Need Due to Lack of Novel Modes of Action991
    Restraints991
      Concerns over the Risks of Addiction Related to Drug Therapy Affect the Prescription Rate991
      Patients Fear that Treatment for Pain will Interfere with Their Cancer Treatment991
      Excessive State Regulation of Analgesics1001
  Pain Management Therapeutics Market for Osteoarthritis Pain1001
    Introduction1001
    Revenue1011
    Branded vs. Generic Share1021
    Annual Cost of Therapy1031
    Treatment Flow Algorithm1041
    Treatment Usage Patterns1051
      Diseased Population1061
      Treatment Seeking Population1071
      Diagnosed Population1081
      Prescription Population1082
    Geographical Segmentation1102
    Drivers and Restraints for the Osteoarthritis Pain Market1121
    Drivers1131
      Rising Prevalence1131
      Rapid Increase of the Obesity Population1131
      Lifestyle Changes Increase the Incidence of Osteoarthritis1131
    Restraints1131
      Pain Management Therapeutics are Associated with Several Side Effects1131
      Low Treatment Seeking and Diagnosis Rates1131
  Pain Management Therapeutics Market for Rheumatoid Arthritis Pain1141
    Introduction1141
    Revenue1142
    Branded vs. Generic Share1161
    Annual Cost of Therapy1171
    Treatment Flow Algorithm1181
    Treatment Usage Patterns1191
      Diseased Population1201
      Treatment Seeking Population1211
      Diagnosed Population1221
      Prescription Population1231
    Geographical Segmentation1242
    Drivers and Restraints for the Rheumatoid Arthritis Market1261
    Drivers1271
      Improvement in Awareness and Resultant Diagnoses Will Drive the Market1271
    Restraints1271
      Inadequate Awareness of Pain Management1271
      Adverse Effects1271
  Pain Management Therapeutics Market for Low Back Pain1271
    Introduction1271
    Revenue1281
    Branded vs. Generic Share1291
    Annual Cost of Therapy1301
    Treatment Flow Algorithm1311
    Treatment Usage Patterns1322
      Diseased Population1341
      Treatment Seeking Population1351
      Diagnosed Population1361
      Prescription Population1371
    Geographical Segmentation1382
    Drivers and Restraints for the Low Back Pain Market1401
    Drivers1411
      Rising Elderly Population Will Drive the Market1411
      Sedentary Lifestyle Increases LBP1411
    Restraints1411
      Low Treatment Seeking Rate and Low Prescription Rate Restricts the Market1411
  Pain Management Therapeutics Market for Post-Operative Pain1411
    Introduction1412
    Revenue1431
    Branded vs. Generic Share1441
    Annual Cost of Therapy1451
    Treatment Flow Algorithm1461
    Treatment Usage Patterns1471
      Diseased Population1481
      Treatment Seeking Population1491
      Diagnosed Population1501
      Prescription Population1502
    Geographical Segmentation1522
    Drivers and Restraints for the Post-Operative Pain Market1541
    Drivers1551
      Substantial Unmet Need Increases Market Potential1551
      Titration of Pain Management Medications is Convenient in a Surgical Facility1551
    Restraints1551
      Expansion of Minimally Invasive Surgical Procedures1551
      Peri-Operative Side Effects1551
Pain Management Therapeutics Market - Geographical Landscape15627
  The US1591
    Revenue1592
    Annual Cost of Therapy1611
    Treatment Usage Patterns1622
      Diseased Population1641
      Treatment Seeking Population1651
      Diagnosed Population1661
      Prescription Population1671
  Top Five Countries in Europe1681
    Revenue1681
    Annual Cost of Therapy1691
    Treatment Usage Patterns1702
      Diseased Population1721
      Treatment Seeking Population1731
      Diagnosed Population1741
      Prescription Population1751
  Japan1761
    Revenue1761
    Annual Cost of Therapy1771
    Treatment Usage Patterns1781
      Diseased Population1791
      Treatment Seeking Population1801
      Diagnosed Population1811
      Prescription Population1821
Pain Management Therapeutics Market - Pipeline Analysis18325
  Introduction1832
    Research and Development Pipeline Fibromyalgia1852
    Research and Development Pipeline Neuropathic Pain1876
    Research and Development Pipeline Migraine1933
    Research and Development Pipeline Cancer Pain1962
    Research and Development Pipeline Osteoarthritis Pain1982
    Research and Development Pipeline Low Back Pain2002
    Research and Development Pipeline Post-Operative Pain2022
  Profiles of Key Late-Stage Drugs in the Pain Management Therapeutics Market2041
    Vimpat (Lacosamide)2041
      Overview2041
      Mechanism of Action2041
    Droxidopa2051
      Mechanism of Action2051

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta" Nov 22, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pain-Management-Therapeutics-Market-to-2017-Price-Competition-to-Intensify-Following-Patent-Expiries-of-Lyrica-and-Cymbalta-2115-301>
  
APA:
GBI Research Reports. (2011). Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta Nov 22, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pain-Management-Therapeutics-Market-to-2017-Price-Competition-to-Intensify-Following-Patent-Expiries-of-Lyrica-and-Cymbalta-2115-301>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.